Avidity Biosciences price target raised to $75 from $65 at Chardan

finance.yahoo.com/news/avidity-biosciences-price-target-raised-132514475.html

In This Article:
Chardan analyst Keay Nakae raised the firm’s price target on Avidity Biosciences (RNA) to $75 from $65 and keeps a Buy rating on the shares after the company announced topline results from the dose escalation portion of the FORTITUDE trial and that it has received written…

This story appeared on finance.yahoo.com, 2025-06-10 13:25:14.
The Entire Business World on a Single Page. Free to Use →